Therapeutic Asset Ratings
8,400 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
cd7-specific car gene-engineered t cells
Extranodal Nasal NK/T Cell Lymphoma
Shenzhen Geno-Immune Medical Institute
P1/2
CCC
(54)
cd7-specific car gene-engineered t cells
T-Lymphoblastic Lymphoma
Shenzhen Geno-Immune Medical Institute
P1/2
CCC
(54)
Cetuximab
Thyroid Gland Carcinoma
Institut de Recherches Internationales Servier
P1/2
CCC
(54)
Chimeric Antigen Receptor Modified T Cells Infusion
Immune System Diseases
UNC Lineberger Comprehensive Cancer Center
P1/2
CCC
(54)
Chimeric Antigen Receptor Modified T Cells Infusion
Immunoproliferative Disorders
UNC Lineberger Comprehensive Cancer Center
P1/2
CCC
(54)
Chimeric Antigen Receptor Modified T Cells Infusion
Lymphatic Diseases
UNC Lineberger Comprehensive Cancer Center
P1/2
CCC
(54)
CIS-DIAMMINEDICHLOROPLATINUM II
Uterine Cancer
Icahn School of Medicine at Mount Sinai
P1/2
CCC
(54)
CIS-DIAMMINEDICHLOROPLATINUM II
Osteosarcoma
Innovent Biologics (Suzhou) Co. Ltd.
P1/2
CCC
(54)
ct103a
Plasma Cell Myeloma
Chunrui Li
P1/2
CCC
(54)
Cyclophosphamide
Ovarian Adenocarcinoma
TCR2 Therapeutics
P1/2
CCC
(54)
Cyclophosphamide
Cutaneous Neoplasm
Obsidian Therapeutics, Inc.
P1/2
CCC
(54)
Cyclophosphamide
Pleural Cancer
Memorial Sloan Kettering Cancer Center
P1/2
CCC
(54)
Cyclophosphamide
Peritoneal Mesothelioma
TCR2 Therapeutics
P1/2
CCC
(54)
Cyclophosphamide
Myxoid/Round Cell Liposarcoma
Sotio Biotech Inc.
P1/2
CCC
(54)
Cyclophosphamide
Pediatric Solid Tumor
Robbie Majzner
P1/2
CCC
(54)
Cyclophosphamide
Ureteral Neoplasms
Eli Lilly and Company
P1/2
CCC
(54)
Cytosin-Arabinosid
Indolent B-cell Non-Hodgkin Lymphoma (iNHL)
Genmab
P1/2
CCC
(54)
DEXAMETHASONE
AIDS-related Peripheral/Systemic Lymphoma
National Cancer Institute (NCI)
P1/2
CCC
(54)
DEXAMETHASONE
Folliculotropic Mycosis Fungoides
City of Hope Medical Center
P1/2
CCC
(54)
Docetaxel
Skin Squamous Cell Carcinoma
Hummingbird Bioscience
P1/2
CCC
(54)
Droxidopa
Autonomic Nervous System Disorder
Vanderbilt University Medical Center
P1/2
CCC
(54)
dt-216p2
Friedreich Ataxia
Design Therapeutics, Inc.
P1/2
CCC
(54)
Durvalumab
Hematopoietic And Lymphoid System Neoplasm
OHSU Knight Cancer Institute
P1/2
CCC
(54)
e7389-lf
Neoplasm
Eisai Co., Ltd.
P1/2
CCC
(54)
Edetate Calcium Disodium
Myelodysplastic Syndrome
M.D. Anderson Cancer Center
P1/2
CCC
(54)
Showing 301 to 325 of 8,400 assets
Previous
Page 13 of 336
Next